Research Overview
Tesamorelin / Ipamorelin Blend is a co-lyophilised research preparation combining two well-characterised growth-hormone secretagogues. Tesamorelin is a 44-amino-acid synthetic analog of human GHRH(1-44), while Ipamorelin is a selective ghrelin-receptor agonist studied for its role in growth-hormone release.
The combination has been studied in research models examining GH-axis signaling, pituitary somatotroph response, pulsatile growth-hormone secretion, and downstream IGF-1 pathway activity. This vial contains a combined lyophilised preparation intended strictly for in-vitro and preclinical research use only.
Mechanism Studied in Research
Tesamorelin has been investigated as a GHRH-receptor agonist that activates pituitary somatotroph signaling and promotes downstream GH-axis activity. Ipamorelin acts through ghrelin-receptor signaling and is commonly studied for selective growth-hormone secretagogue activity.
When evaluated together, the blend is used in research models examining complementary receptor activation, growth-hormone pulse behavior, downstream IGF-1 signaling, and endocrine pathway modulation under controlled laboratory conditions.
Research Applications
Visceral-adipose research models. Tesamorelin has been studied in literature involving visceral adipose tissue dynamics, while the blend has been used in research examining GH-axis effects on body-composition markers.
GH-IGF-1 axis characterization. Researchers use Tesamorelin / Ipamorelin to evaluate GHRH-receptor signaling, ghrelin-receptor activity, GH release patterns, and downstream IGF-1 pathway responses.
Metabolic and hepatic-lipid research. Tesamorelin has been investigated in research models involving hepatic triglyceride content, lipid-droplet morphology, and gene-expression signatures linked to lipid handling.
Neuroendocrine and cognition-adjacent models. Published work involving Tesamorelin has explored hypothalamic signaling and GH-axis related pathway activity in controlled research settings.
Reconstitution Reference
The 10mg combined vial is reconstituted using bacteriostatic water. A common laboratory example uses 2mL of bacteriostatic water, producing a final concentration of 5mg per mL.
The diluent should be introduced slowly along the inner wall of the vial while avoiding direct impact on the powder cake. The vial should be gently rolled or swirled until the powder dissolves fully. Vigorous shaking should be avoided.
After reconstitution, label the vial with the reconstitution date, diluent used, concentration, and batch number. This product is supplied for laboratory research only.
Storage and Handling
Lyophilised vials should be stored at -20°C in the original sealed packaging, protected from direct light and moisture. Once reconstituted with bacteriostatic water, the solution should be stored at 2-8°C in a dedicated laboratory refrigerator.
Repeated freeze-thaw cycles should be avoided. If extended storage is required, researchers may aliquot material into sterile low-protein-binding tubes according to validated laboratory protocols.
Vials should be labelled with reconstitution date and concentration to support traceability and institutional documentation practice.
References
[2] Stanley TL et al. (2019). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation.
[3] Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue.
[4] Stanley TL et al. (2015). Tesamorelin reduces liver fat in HIV-infected patients with hepatic steatosis.